Pregabalin Capsule
Product Images NDC 80425-0185

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0185). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Equation)

A formula for creatinine clearance (CLCr) calculation shown as an equation incorporating age, weight, serum creatinine, and a correction factor for female patients.*

FDA Label Image

Fig 1 (Fig 1)

A line chart depicting the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg three times a day, Pregabalin 150 mg three times a day, Pregabalin 75 mg three times a day, and placebo, showing trends in patient improvement across increasing pain relief percentages.*

FDA Label Image

Fig 10 (Fig 10)

A Kaplan-Meier survival curve chart showing the estimated percentage of subjects without LTR (likely a clinical outcome) over 180 days, comparing two groups: Pregabalin and Placebo. The y-axis represents the estimated percentage of subjects without LTR, and the x-axis shows time in days. The Pregabalin group has a higher percentage of subjects without LTR throughout the 180-day period compared to the Placebo group.*

FDA Label Image

Fig 11 (Fig 11)

A line graph showing percent of subjects improved versus percent improved from baseline to Week 12 BOCF. It compares outcomes for Pregabalin and Placebo groups, with percent improvement on the horizontal axis and percent of subjects improved on the vertical axis.*

FDA Label Image

Fig 12 (Fig 12)

A line graph comparing the percent of subjects improved from baseline to Week 16 using the Brief Overactive Bladder Questionnaire (BOCF) between Pregabalin and Placebo groups. The x-axis represents percent improvement from baseline to Week 16 BOCF, and the y-axis shows the percent of subjects improved. The graph features two lines: a solid line for Pregabalin and a dashed line for Placebo, with Pregabalin consistently showing higher improvement percentages across the range.*

FDA Label Image

Fig 2 (Fig 2)

A line chart showing the percent of patients improved on the vertical axis against percent improvement in pain from baseline on the horizontal axis, comparing Pregabalin 100 mg three times a day with placebo. The chart illustrates higher patient improvement rates for Pregabalin compared to placebo across various improvement thresholds.*

FDA Label Image

Fig 3 (Fig 3)

A line graph depicting the percent of patients improved plotted against percent improvement in pain from baseline for Pregabalin at different doses (75 mg, 150 mg, and 300 mg twice a day) compared to placebo. The graph shows multiple curves representing each treatment group over a range of pain improvement percentages.*

FDA Label Image

Fig 4 (Fig 4)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows three distinct curves indicating the effectiveness of each treatment over a range of pain improvement percentages.*

FDA Label Image

Fig 5 (Fig 5)

Line chart showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph compares the effectiveness of two Pregabalin dosages to placebo over a range of pain improvement percentages.*

FDA Label Image

Fig 6 (Fig 6)

Bar chart comparing responder rates (%) for pregabalin in two studies, Study E1 and Study E3. The chart shows increasing responder rates with higher pregabalin doses (50 mg to 600 mg/day) compared to placebo. Study E1 includes BID dosing at multiple doses, showing rates from 15% to 51%. Study E3 shows rates for placebo, 600 mg BID, and 600 mg TID dosing, with responder rates from 9% to 49%.*

FDA Label Image

Fig 7 (Fig 7)

A line graph showing seizure reduction as median percent change from baseline versus dose (mg/day) for pregabalin across three studies (E1 BID, E2 TID, and E3 BID/TID). The graph includes dose points at 0, 50, 150, 300, and 600 mg/day with significant p-values indicating statistical significance for reductions in seizure frequency compared to placebo.*

FDA Label Image

Fig 9 (Fig 9)

A line graph depicting the percent of patients improved by the percent improvement in pain from baseline for Pregabalin at various daily doses (600 mg, 450 mg, 300 mg) compared to placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percent of patients improved, with higher doses showing greater improvement trends.*

FDA Label Image

Pregabalin #90 (Pregabalin 150mg Cap Qty 90 80425 0185)

Label from a prescription drug package of PREGABALIN 150 MG CAPSULE by Advanced Rx Pharmacy of Tennessee, LLC. The label includes the NDC 0240-8153-03 and source NDC 67877-0466-90. It shows lot number 90PRE1501221 with expiration date 9/30/2022, and storage instructions at room temperature 20°-25°C (68°-77°F). Additional cautionary text about federal law is present.*

FDA Label Image

Structure (Structure)

Chemical structure of pregabalin, illustrating its molecular arrangement with labeled functional groups including an amino group and a carboxylic acid group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.